Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 15, 2022.
The study examined ozoralizumab without concomitant therapy, as methotrexate cannot be given to all patients with rheumatoid arthritis due to inadequate efficacy and tolerability.
Preventing chronic damage accrual is one of the top treatment targets, as it is linked to increased mortality and decreased quality of life.
The neutralizing serum activity against variants in patients receiving methotrexate only increased 20-23-fold after booster vaccination, while the serum activity in those in the non-immunosuppressed group increased 67-73-fold.
Supplementation with probiotics was shown to improve hyperuricemia and symptoms of gout, among other inflammatory diseases such as juvenile arthritis (JIA), osteoarthritis (OA), osteoporosis and osteopenia, inflammatory bowel disease (IBD), spondyloarthritis, rheumatoid arthritis (RA), and psoriasis (PsO).
How much do you know about the Rheumatic Disease Report Card and how it relates to your practice? Test your knowledge with this quiz.